Claim 70% Off TipRanks This Holiday Season
- Unlock hedge-fund level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Sarepta Therapeutics ( (SRPT) ) just unveiled an update.
On December 10, 2025, Sarepta Therapeutics, Inc. entered into privately negotiated exchange agreements with certain holders of its 1.25% Convertible Senior Notes due 2027, including an entity affiliated with board member Michael Chambers, to exchange approximately $291.4 million in principal of the existing notes for an equal principal amount of new 4.875% Convertible Senior Notes due 2030 plus about $31.6 million in cash. The new notes were issued on December 18, 2025, under an existing indenture and form part of the same series as the $602.0 million of 4.875% Convertible Senior Notes due 2030 issued in August 2025, bringing the total outstanding principal of that 2030 series to approximately $893.4 million and effectively extending the company’s debt maturity profile while modestly increasing its cash outlay to participating noteholders.
The most recent analyst rating on (SRPT) stock is a Hold with a $17.00 price target. To see the full list of analyst forecasts on Sarepta Therapeutics stock, see the SRPT Stock Forecast page.
Spark’s Take on SRPT Stock
According to Spark, TipRanks’ AI Analyst, SRPT is a Neutral.
Sarepta Therapeutics’ overall stock score is primarily impacted by its financial performance challenges, including inconsistent profitability and negative cash flows. Technical analysis provides a mixed outlook with short-term bullish momentum but potential bearish signals. Valuation remains a concern due to the negative P/E ratio. The earnings call offered some positive insights, but significant challenges persist.
To see Spark’s full report on SRPT stock, click here.
More about Sarepta Therapeutics
Sarepta Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing genetic medicines, notably in rare diseases such as Duchenne muscular dystrophy, using platforms including RNA and gene therapy.
Average Trading Volume: 5,114,693
Technical Sentiment Signal: Sell
Current Market Cap: $2.22B
For a thorough assessment of SRPT stock, go to TipRanks’ Stock Analysis page.